Literature DB >> 19883799

Travels and travails of autoimmunity: a historical journey from discovery to rediscovery.

Ian R Mackay1.   

Abstract

Consideration on autoimmunity began, as did immunology itself, around year 1900, first with Ehrlich's doctrine of 'horror autotoxicus', then interpreted as 'autoimmunity cannot happen'. Yet by 1904 the antibody nature of the autohemolysin responsible for cold hemoglobinuria was described, and soon confirmed, but without generating any durable concept on autoimmunization as a cause of disease. Reasons included Ehrlich's doctrine, the particular directions that immunology was to take after the initial advances, and a greater preoccupation with bodily responses to extrinsic rather than autologous substances. So, during 1915-1945, autoimmunity underwent a long eclipse despite, during this time, some potentially telling studies relating to brain, kidney and other diseases. The 'awakening' dates from 1945 when a general theoretical concept did appear feasible. Knowledge accrued from applications of several research undertakings mostly for purposes quite unrelated to the proof of autoimmunization: the use of adjuvants; the Coombes anti-globulin reaction; the Waaler-Rose rheumatoid factor; Hargraves' LE cell; the Witebsky-Rose experimental induction of thyroiditis with autologous thyroid gland, and others. By the early 1960s resistance to the idea of autoimmunization had weakened, perhaps hastened by a monograph on autoimmune disease published in 1963, and surely by the consensus reached at a large international conference published as proceedings in 1965. This present conspectus arbitrarily concludes at year 1965, recognizing that the history of autoimmunity even now is far from over. 2009. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19883799     DOI: 10.1016/j.autrev.2009.10.007

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  25 in total

Review 1.  Epidemiology of environmental exposures and human autoimmune diseases: findings from a National Institute of Environmental Health Sciences Expert Panel Workshop.

Authors:  Frederick W Miller; Lars Alfredsson; Karen H Costenbader; Diane L Kamen; Lorene M Nelson; Jill M Norris; Anneclaire J De Roos
Journal:  J Autoimmun       Date:  2012-06-25       Impact factor: 7.094

2.  The persistent challenge of lupus nephritis.

Authors:  Guido Valesini; Fabrizio Conti
Journal:  Clin Rev Allergy Immunol       Date:  2011-06       Impact factor: 8.667

3.  Reproductive immunology: a focus on the role of female sex hormones and other gender-related factors.

Authors:  Elena Peeva
Journal:  Clin Rev Allergy Immunol       Date:  2011-02       Impact factor: 8.667

4.  Geographical differences in autoantibodies and anti-infectious agents antibodies among healthy adults.

Authors:  Yinon Shapira; Bat-Sheva Poratkatz; Boris Gilburd; Ori Barzilai; Maya Ram; Miri Blank; Staffan Lindeberg; Johan Frostegård; Juan-Manuel Anaya; Nicola Bizzaro; Luis J Jara; Jan Damoiseaux; Yehuda Shoenfeld; Nancy Agmon Levin
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

5.  Cutting-edge issues in organ-specific autoimmunity.

Authors:  M Eric Gershwin; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2011-10       Impact factor: 8.667

Review 6.  Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity.

Authors:  Jolien Suurmond; Betty Diamond
Journal:  J Clin Invest       Date:  2015-05-04       Impact factor: 14.808

Review 7.  Autoimmune diseases - connecting risk alleles with molecular traits of the immune system.

Authors:  Maria Gutierrez-Arcelus; Stephen S Rich; Soumya Raychaudhuri
Journal:  Nat Rev Genet       Date:  2016-02-15       Impact factor: 53.242

8.  The future of autoimmunity.

Authors:  Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

9.  Tolerance, loss of tolerance and regaining tolerance to self by immune-mediated events.

Authors:  Arpad Zsigmond Barabas; Chad Douglas Cole; Richard Milton Graeff; Rene Lafreniere; Donald Mackay Weir
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

10.  MicroRNA-155 confers encephalogenic potential to Th17 cells by promoting effector gene expression.

Authors:  Ruozhen Hu; Thomas B Huffaker; Dominique A Kagele; Marah C Runtsch; Erin Bake; Aadel A Chaudhuri; June L Round; Ryan M O'Connell
Journal:  J Immunol       Date:  2013-05-17       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.